CliffBio
biologic

Eloctate

Antihemophilic Factor (Recombinant), Fc Fusion protein

Loss of exclusivityJanuary 2029projected — 12-year biologic exclusivity estimate
CompanyBioverativ →View the full company profile on CliffBio

Drug detail

Brand nameEloctate
Active ingredientAntihemophilic Factor (Recombinant), Fc Fusion protein
Strength6000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2017
Marketing statusRx

More from Bioverativ

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Eloctate patent cliff — loss of exclusivity January 2029 | CliffBio